glp 1 agonist weight loss comparison Comparing GLP-type therapies for in those without diabetes. Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual (#tirzepatide) have been FDA-approved for #weightloss in adults comparison of glp 1 agonists

There was no difference between the groups in the number of procedural complications or adverse events

J.et al

Semaglutide, better known by brand names such as Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist drug that has been approved by the U.S

Evidence among individuals overweight/obesity without diabetes Larger BP reductions have been observed in RCTs evaluating GLP-1 RAs for weight management among individuals with overweight or obesity without diabetes (Table 2)

R.WefersJ.MeierJ

doi: 10.1001/jamanetworkopen.2024.21305 [DOI] [PMC free article] [PubMed] [Google Scholar] 12.Bezin J, Gouverneur A, Pnichon M, et al